A
Adial Pharmaceuticals
ADial: Pharmacotherapeutics for dependence-related diseases
About Adial Pharmaceuticals
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for addiction and related disorders. Founded in November 2010 by Bankole A. Johnson and William B. Stilley, the company is headquartered in Glen Allen, Virginia, and has been publicly traded on NASDAQ under the ticker ADIL since July 2018. The company's creation stemmed from pioneering research into the genetics of addiction that began in the 1990s, which led to Adial licensing its core technology from the University of Virginia.
The founders' backgrounds are central to Adial's mission. Dr. Bankole A. Johnson is a world-renowned neuroscientist and psychiatrist who pioneered the development of medications for alcohol abuse and invented the patents covering AD04. His extensive research in the neuropsychopharmacology of addictions provides the scientific foundation for the company. William B. Stilley, who has served as CEO since the company's inception, brings a background in business, finance, and prior experience in the life sciences sector, including managing clinical trials and M&A transactions. His journey into biotech was driven by a desire to develop products that create significant human value. This blend of deep scientific expertise and seasoned business leadership guides the company's strategy.
Adial's core business revolves around the development and future commercialization of its lead product candidate, AD04, a therapeutic agent for treating Alcohol Use Disorder (AUD). The company operates in the biopharmaceutical market, targeting a significant unmet medical need. Its business model is centered on obtaining regulatory approval for AD04 and then generating revenue through pharmaceutical product sales. The company’s strategy involves partnering with academic institutions for clinical trials and potentially forming strategic licensing partnerships with larger pharmaceutical companies. Adial's lead investigational drug, AD04, is a genetically targeted, selective serotonin-3 (5-HT3) antagonist designed to reduce the craving for alcohol. The therapy is intended for patients with specific genetic markers, which are identified using a proprietary companion diagnostic genetic test. This personalized medicine approach reframes AUD as a treatable genetic condition, potentially reducing stigma and increasing patient acceptance. Post-hoc analysis of clinical trials showed that AD04 significantly reduced heavy drinking days in the targeted patient population with a safety profile comparable to a placebo. The oral, twice-daily tablet is non-addictive and aims to allow for the management of heavy drinking rather than requiring complete abstinence, a major hurdle for many patients.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2007
- Headquarters
- Glen Allen, United States
- Listing
- IPO 2018
- Sector
- Biotech & Life Sciences
News
Open roles
Adial Pharmaceuticals in the Glen Allen ecosystem
The Adial Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
Bespoke Growth Partners
Keystone Capital Partners
Alumni Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Adial Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Adial Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

